William J. Rieflin's Insider Trades & SAST Disclosures
William J. Rieflin's most recent trade in Lyell Immunopharma Inc was a trade of 130,000 Option (right to buy) done . Disclosure was reported to the exchange on June 14, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern William J. Rieflin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 130,000 | 130,000 | - | - | Option (right to buy) | |
| RAPT Therapeutics Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 36,490 | 36,490 | - | - | Stock Option (right to buy) | |
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director | 05 Apr 2024 | 2,769,168 | 0 (0%) | 4% | - | Common Stock | ||
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 225,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 80,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 80,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 78,407 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 75,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director | 05 Apr 2024 | 5,172 | 0 (0%) | 0% | - | Common Stock | ||
| RAPT Therapeutics Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 11,871 | 11,871 | - | - | Stock Option (right to buy) | |
| Lyell Immunopharma Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| RAPT Therapeutics Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 12,940 | 12,940 | - | - | Stock Option (right to buy) | |
| RAPT Therapeutics Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 6,026 | 6,026 | - | - | Stock Option (right to buy) | |
| Lyell Immunopharma Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| RAPT Therapeutics Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 8,500 | 8,500 | - | - | Stock Option (right to buy) | |
| RAPT Therapeutics Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 5,207 | 5,207 | - | - | Stock Option (right to buy) | |
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| RAPT Therapeutics Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Ngm Biopharmaceuticals Inc | William J. Rieflin | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| RAPT Therapeutics Inc | William J. Rieflin | Director | Purchase of securities on an exchange or from another person at price $ 16.22 per share. | 19 Nov 2020 | 10,000 | 18,000 (0%) | 0% | 16.2 | 162,200 | Common Stock |
| RAPT Therapeutics Inc | William J. Rieflin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges